US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US5681941A
(en)
*
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5459255A
(en)
*
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US6001988A
(en)
*
|
1990-06-11 |
1999-12-14 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands to lectins
|
US6153595A
(en)
*
|
1990-08-16 |
2000-11-28 |
Isis Pharmaceuticals Inc. |
Composition and method for treatment of CMV infections
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
DK0618925T4
(da)
*
|
1991-12-24 |
2012-07-09 |
Isis Pharmaceuticals Inc |
Antisense-oligonukleotider
|
US20060270624A1
(en)
*
|
1991-12-24 |
2006-11-30 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US6537973B1
(en)
|
1992-03-16 |
2003-03-25 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide inhibition of protein kinase C
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US20030013670A1
(en)
*
|
1992-10-05 |
2003-01-16 |
Monia Brett P. |
Antisense oligonucleotide inhibition of ras
|
US6784290B1
(en)
|
1992-10-05 |
2004-08-31 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
US5872242A
(en)
*
|
1992-10-05 |
1999-02-16 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of ras
|
EP0670897A4
(de)
*
|
1992-10-05 |
1997-08-06 |
Isis Pharmaceuticals Inc |
HEMMUNG DES ras-GENS MIT GEGENLÄUFIGEN OLIGONUKLEOTIDEN.
|
US5985558A
(en)
|
1997-04-14 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
|
GB9301000D0
(en)
*
|
1993-01-20 |
1993-03-10 |
Glaxo Group Ltd |
Chemical compounds
|
DE69433036T2
(de)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Aminoderivatisierte nukleoside und oligonukleoside
|
US5801154A
(en)
*
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
US5981731A
(en)
*
|
1994-05-31 |
1999-11-09 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of B-raf gene expression
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5912340A
(en)
*
|
1995-10-04 |
1999-06-15 |
Epoch Pharmaceuticals, Inc. |
Selective binding complementary oligonucleotides
|
US5854033A
(en)
|
1995-11-21 |
1998-12-29 |
Yale University |
Rolling circle replication reporter systems
|
US6635417B1
(en)
*
|
1996-07-31 |
2003-10-21 |
California Institute Of Technology |
Complex formation between DSDNA and oligomer of cyclic heterocycles
|
US6555692B1
(en)
|
1996-02-26 |
2003-04-29 |
California Institute Of Technology |
Preparation and use of bifunctional molecules having DNA sequence binding specificity
|
US5744460A
(en)
*
|
1996-03-07 |
1998-04-28 |
Novartis Corporation |
Combination for treatment of proliferative diseases
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US6111085A
(en)
*
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
US6001991A
(en)
*
|
1996-10-04 |
1999-12-14 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
|
US7235653B2
(en)
*
|
1996-12-31 |
2007-06-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US20040023917A1
(en)
*
|
1996-12-31 |
2004-02-05 |
Bennett C. Frank |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6077833A
(en)
*
|
1996-12-31 |
2000-06-20 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US6127533A
(en)
*
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6576752B1
(en)
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
US6251591B1
(en)
|
1997-02-27 |
2001-06-26 |
Lorne Park Research, Inc. |
Quantitative method for detecting nucleotide concentration
|
US6046004A
(en)
*
|
1997-02-27 |
2000-04-04 |
Lorne Park Research, Inc. |
Solution hybridization of nucleic acids with antisense probes having modified backbones
|
EP0866071B1
(de)
*
|
1997-03-20 |
2004-10-20 |
F. Hoffmann-La Roche Ag |
Modifizierte Primer
|
AU731909B2
(en)
|
1997-07-01 |
2001-04-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US20070149472A1
(en)
*
|
1997-08-13 |
2007-06-28 |
Mckay Robert |
Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
|
US5877309A
(en)
|
1997-08-13 |
1999-03-02 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against JNK
|
US6809193B2
(en)
|
1997-08-13 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US6133246A
(en)
*
|
1997-08-13 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
WO1999021874A1
(fr)
*
|
1997-10-27 |
1999-05-06 |
Sankyo Company, Limited |
Oligodesoxyribonucleotides contenant un nucleoside modifie et autre
|
US20040171564A1
(en)
*
|
1997-11-20 |
2004-09-02 |
Honkanen Richard E. |
Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
|
US5948902A
(en)
*
|
1997-11-20 |
1999-09-07 |
South Alabama Medical Science Foundation |
Antisense oligonucleotides to human serine/threonine protein phosphatase genes
|
US5968748A
(en)
*
|
1998-03-26 |
1999-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human HER-2 expression
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
JP2002515514A
(ja)
*
|
1998-05-21 |
2002-05-28 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
オリゴヌクレオチドの局所送逹のための組成物及び方法
|
AU745880B2
(en)
*
|
1998-05-21 |
2002-04-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US6255050B1
(en)
|
1998-05-22 |
2001-07-03 |
Lorne Park Research, Inc. |
Dynamic hybridization system
|
US6300319B1
(en)
|
1998-06-16 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Targeted oligonucleotide conjugates
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6673912B1
(en)
|
1998-08-07 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
2′-O-aminoethyloxyethyl-modified oligonucleotides
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
US20040009938A1
(en)
*
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
US6175004B1
(en)
|
1998-09-01 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6069243A
(en)
*
|
1998-10-06 |
2000-05-30 |
Isis Pharmaceuticals, Inc. |
Process for oligonucleotide synthesis
|
US6492111B1
(en)
*
|
1998-11-25 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
In situ binary synthesis of biologically effective molecules
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US6399765B1
(en)
|
1999-03-17 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Methods for removing dimethoxytrityl groups from oligonucleotides
|
US6235891B1
(en)
|
1999-03-31 |
2001-05-22 |
South Alabama Medical Science Foundation |
Glucocorticoid receptor agonist and decreased PP5
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6277982B1
(en)
|
1999-08-20 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates
|
DE19945503A1
(de)
*
|
1999-09-23 |
2001-04-05 |
Henkel Kgaa |
Mehrphasiges Reinigungsmittel mit antimikrobieller Wirkung
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US7105962B2
(en)
*
|
2000-08-03 |
2006-09-12 |
Matsushita Electric Industrial Co., Ltd. |
Brushless motor for partable electronic equipment with wire treatment technique of coils
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
WO2002030465A2
(en)
|
2000-10-12 |
2002-04-18 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US6573051B2
(en)
*
|
2001-03-09 |
2003-06-03 |
Molecular Staging, Inc. |
Open circle probes with intramolecular stem structures
|
ATE434936T1
(de)
|
2001-03-14 |
2009-07-15 |
Myriad Genetics Inc |
Tsg101-gag-wechselwirkung und ihre verwendung
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
DK2000545T3
(da)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
|
CA2451643C
(en)
|
2001-06-21 |
2012-11-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
EP2174953A1
(de)
|
2001-09-18 |
2010-04-14 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7553619B2
(en)
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
ITBO20020198A1
(it)
*
|
2002-04-12 |
2003-10-13 |
Univ Bologna |
Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
|
JP2005536190A
(ja)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
ATE474045T1
(de)
|
2002-05-30 |
2010-07-15 |
Sloan Kettering Inst Cancer |
Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
|
EP2116604A1
(de)
|
2002-08-05 |
2009-11-11 |
University of Rochester |
Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
|
US6884880B2
(en)
|
2002-08-21 |
2005-04-26 |
Ash Stevens, Inc. |
Process for the preparation of 9-β-anomeric nucleoside analogs
|
EP2322535A3
(de)
|
2002-09-20 |
2011-09-28 |
Yale University |
Riboswitches, Verfahren für deren Anwendung, Zusammensetzungen damit
|
US7229976B2
(en)
|
2002-09-26 |
2007-06-12 |
Isis Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AU2003290598A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
CA2506127C
(en)
|
2002-11-15 |
2013-07-09 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
US8007804B2
(en)
|
2002-11-15 |
2011-08-30 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
EP2410332A1
(de)
|
2002-11-21 |
2012-01-25 |
The University Of Utah |
Methode zur Identifizierung von purinergen Modulatoren des Geruchssystems
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US9487823B2
(en)
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
WO2004058987A2
(en)
|
2002-12-20 |
2004-07-15 |
Qiagen Gmbh |
Nucleic acid amplification
|
US6977153B2
(en)
*
|
2002-12-31 |
2005-12-20 |
Qiagen Gmbh |
Rolling circle amplification of RNA
|
US7468356B2
(en)
|
2003-02-11 |
2008-12-23 |
Antisense Therapeutics Ltd. |
Modulation of insulin like growth factor I receptor expression
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
ATE479752T1
(de)
|
2003-03-07 |
2010-09-15 |
Alnylam Pharmaceuticals Inc |
Therapeutische zusammensetzungen
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
EP2660322A3
(de)
|
2003-04-17 |
2013-11-13 |
Alnylam Pharmaceuticals Inc. |
Modifizierte iRNA-Wirkstoffe
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US7960355B2
(en)
*
|
2003-05-23 |
2011-06-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of the expression of B7 protein
|
US7897582B2
(en)
*
|
2003-05-23 |
2011-03-01 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
US7276599B2
(en)
|
2003-06-02 |
2007-10-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
US7786290B2
(en)
|
2003-06-13 |
2010-08-31 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
PT1660057E
(pt)
|
2003-08-27 |
2012-08-02 |
Ophthotech Corp |
Terapia de associação para o tratamento de distúrbios neovasculares oculares
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
NZ545134A
(en)
|
2003-09-18 |
2009-06-26 |
Lilly Co Eli |
Modulation of eIF4E expression
|
AU2004274021B2
(en)
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
US7125945B2
(en)
*
|
2003-09-19 |
2006-10-24 |
Varian, Inc. |
Functionalized polymer for oligonucleotide purification
|
EP1678194B1
(de)
|
2003-10-10 |
2013-06-26 |
Alchemia Oncology Pty Limited |
Modulation der synthese und des abbaus von hyaluronan bei der behandlung von krankheiten
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ES2493016T3
(es)
|
2003-11-17 |
2014-09-11 |
Genentech, Inc. |
Composiciones que comprenden anticuerpos contra CD79b conjugados a un agente inhibidor del crecimiento o un agente citotóxico y procedimientos para el tratamiento de tumores de origen hematopoyético
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8778900B2
(en)
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
EP2540734B1
(de)
|
2004-04-05 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Prozess und Reagenzien für Oligonukleotidsynthese und -reinigung
|
EP1750776A2
(de)
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonukleotide mit c5-modifiziertem pyrimidin
|
DK1773872T3
(en)
|
2004-05-21 |
2017-05-08 |
Uab Res Found |
VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
JP5192234B2
(ja)
|
2004-08-10 |
2013-05-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
化学修飾オリゴヌクレオチド
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006032144A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Arc Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US20060166234A1
(en)
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US9944713B2
(en)
|
2004-11-24 |
2018-04-17 |
Medicinal Bioconvergence Research Center |
Antibody specific to the AIMP2-DX2
|
CA2620626C
(en)
|
2004-12-20 |
2011-06-07 |
Isu Abxis Co., Ltd. |
Molecules inhibiting intercellular adhesion
|
US8067175B2
(en)
|
2005-02-11 |
2011-11-29 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for detecting a drug resistant EGFR mutant
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
US7476733B2
(en)
|
2005-03-25 |
2009-01-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
|
EP1863908B1
(de)
|
2005-04-01 |
2010-11-17 |
Qiagen GmbH |
Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
|
JP5329949B2
(ja)
|
2005-05-31 |
2013-10-30 |
エコーレ ポリテクニーク フェデラーレ デ ローザンヌ |
遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
|
EP1895841A4
(de)
*
|
2005-06-14 |
2010-08-18 |
Univ Brigham Young |
Verfahren zur selektiven n-9-glycosylierung von purinen
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
GB0514809D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
EP1929012B1
(de)
|
2005-08-11 |
2010-10-06 |
Synthetic Genomics, Inc. |
Verfahren zur in vitro-rekombination
|
AU2006281569A1
(en)
|
2005-08-17 |
2007-02-22 |
Medexis S.A. |
Composition and method for determination of CK19 expression
|
WO2007027775A2
(en)
|
2005-08-29 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
EP2096170B1
(de)
|
2005-09-19 |
2011-08-10 |
Isis Pharmaceuticals, Inc. |
Modulation der Glucagonrezeptorexpression
|
EA200800868A1
(ru)
|
2005-09-19 |
2008-10-30 |
ДЖОНСОН ЭНД ДЖОНСОН ФАРМАСЬЮТИКАЛ РИСЕРЧ ЭНД ДИВЕЛОПМЕНТ, Эл. Эл. Си. |
Модуляция экспрессии глюкокортикоидного рецептора
|
EP2189522A1
(de)
|
2005-10-14 |
2010-05-26 |
MUSC Foundation For Research Development |
PAX2 als Ziel zur Induktion einer Immunität gegen DEFB1-vermittelte Tumore und bei der Krebstherapie
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP2325315B1
(de)
|
2005-10-28 |
2014-05-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Huntingtin-Gens
|
WO2007056331A2
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
EP1966377A2
(de)
|
2005-11-21 |
2008-09-10 |
Isis Pharmaceuticals, Inc. |
Modulation der eif4e-bp2-expression
|
JP2009524411A
(ja)
*
|
2005-12-21 |
2009-07-02 |
イェール ユニバーシティー |
リボスイッチの調節に関連した方法および組成物
|
JP2009522281A
(ja)
|
2005-12-28 |
2009-06-11 |
トランスレーショナル セラピューティクス,インク. |
翻訳機能障害に基づく治療法
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
6−修飾された二環式核酸類似体
|
JP5213723B2
(ja)
|
2006-01-27 |
2013-06-19 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
マイクロrnaの調節に使用するためのオリゴマー化合物及び組成物
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
US7820883B2
(en)
*
|
2006-03-15 |
2010-10-26 |
Dow Agrosciences Llc |
Resistance to auxinic herbicides
|
CA2873833A1
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
WO2007125173A2
(en)
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
WO2007134014A2
(en)
|
2006-05-05 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of gcgr
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
CN103614375A
(zh)
|
2006-05-11 |
2014-03-05 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
ES2389737T3
(es)
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en 5'
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
WO2008097328A2
(en)
*
|
2006-06-23 |
2008-08-14 |
Northwestern University |
Asymmetric functionalized nanoparticles and methods of use
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
AU2007281082A1
(en)
*
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of JNK proteins
|
EP2061799A4
(de)
*
|
2006-09-11 |
2010-12-22 |
Univ Yale |
Verfahren und zusammensetzungen zur verwendung von lysin-riboswitches
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
WO2008036825A2
(en)
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
WO2008042156A1
(en)
*
|
2006-09-28 |
2008-04-10 |
Northwestern University |
Maximizing oligonucleotide loading on gold nanoparticle
|
MX363224B
(es)
|
2006-10-03 |
2019-03-15 |
Alnylam Pharmaceuticals Inc |
Formulaciones que contienen lipidos.
|
CA2665536C
(en)
|
2006-10-05 |
2016-02-16 |
Massachusetts Institute Of Technology |
Multifunctional encoded particles for high-throughput analysis
|
EP2104516B1
(de)
|
2006-11-01 |
2015-01-07 |
University of Rochester |
Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
|
CA2672297A1
(en)
|
2006-12-11 |
2008-06-19 |
University Of Utah Research Foundation |
Compositions and methods for treating pathologic angiogenesis and vascular permeability
|
EP2913341A1
(de)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Verfahren für den Nachweis von Augenerkrankungen und leiden sowie ihre Behandlung
|
CA2691066C
(en)
|
2007-02-09 |
2018-07-31 |
Northwestern University |
Particles for detecting intracellular targets
|
JP2010521460A
(ja)
*
|
2007-03-12 |
2010-06-24 |
アンティジェン・エクスプレス・インコーポレーテッド |
癌免疫療法におけるIi−RNAi関与Ii抑制
|
JP5750209B2
(ja)
*
|
2007-03-16 |
2015-07-15 |
アプタ バイオサイエンス リミテッド |
機能性分子、機能性分子合成用アミダイド、及び標的物質解析方法
|
AU2008227458A1
(en)
|
2007-03-22 |
2008-09-25 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
AP3018A
(en)
|
2007-03-29 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
CN101686939B
(zh)
*
|
2007-04-17 |
2013-03-27 |
巴克斯特国际公司 |
用于肺部投送的核酸微粒
|
US20100221821A1
(en)
*
|
2007-05-29 |
2010-09-02 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing and rna processing
|
WO2008156987A2
(en)
|
2007-05-29 |
2008-12-24 |
Yale University |
Riboswitches and methods and compositions for use of and with riboswitches
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
EP2826863B1
(de)
|
2007-05-30 |
2017-08-23 |
Northwestern University |
Nukleinsäurefunktionalisierte Nanopartikel für therapeutische Anwendungen
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
US20100184823A1
(en)
|
2007-07-05 |
2010-07-22 |
Mark Aron Labow |
dsRNA For Treating Viral Infection
|
US8278283B2
(en)
|
2007-07-05 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
6-disubstituted or unsaturated bicyclic nucleic acid analogs
|
AU2008286771B2
(en)
|
2007-08-15 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
WO2009032702A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
WO2009032693A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
WO2009032057A2
(en)
|
2007-08-29 |
2009-03-12 |
Adam Lubin |
Method for the selective therapy of disease
|
WO2009039300A2
(en)
*
|
2007-09-18 |
2009-03-26 |
Intradigm Corporation |
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
CA2704737A1
(en)
*
|
2007-09-18 |
2009-09-03 |
Intradigm Corporation |
Compositions comprising k-ras sirna and methods of use
|
US8445217B2
(en)
|
2007-09-20 |
2013-05-21 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
CA2708173C
(en)
|
2007-12-04 |
2016-02-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
EP3100718B1
(de)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
|
EP2265627A2
(de)
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexitolnukleinsäureanaloga
|
WO2009102427A2
(en)
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
CN102014932B
(zh)
|
2008-03-05 |
2015-11-25 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
US20110105588A1
(en)
*
|
2008-03-12 |
2011-05-05 |
Intradigm Corporation |
Compositions comprising notch1 sirna and methods of use thereof
|
WO2009117589A1
(en)
*
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
EP2285819B1
(de)
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
|
WO2009124295A2
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
CA2721183C
(en)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
MX2010011508A
(es)
|
2008-04-18 |
2011-05-03 |
Baxter Int |
Composicion basada en microesferas para prevenir y/o revertir la nueva presentacion de diabetes autoinmune.
|
EP2280995A2
(de)
*
|
2008-04-29 |
2011-02-09 |
Wyeth LLC |
Verfahren zur behandlung von entzündungen
|
WO2010006973A2
(en)
*
|
2008-07-15 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of tgf-beta receptor genes
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
WO2010017248A2
(en)
|
2008-08-04 |
2010-02-11 |
University Of Miami |
Sting (stimulator of interferon genes), a regulator of innate immune responses
|
EP3081648A1
(de)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
|
EP2331690B1
(de)
|
2008-09-02 |
2016-01-13 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression eines mutierten egfr-gens
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
EP3587434A1
(de)
|
2008-09-23 |
2020-01-01 |
Alnylam Pharmaceuticals Inc. |
Chemische modifikationen von monomeren und oligonukleotiden mit click komponenten um liganden zu konjugieren
|
US8501805B2
(en)
|
2008-09-24 |
2013-08-06 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-L-bicyclic nucleosides
|
US8604192B2
(en)
*
|
2008-09-24 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acids analogs
|
EP2334793B1
(de)
|
2008-09-25 |
2016-04-06 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
|
ES2727549T3
(es)
|
2008-10-03 |
2019-10-17 |
Curna Inc |
Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
|
ES2475065T3
(es)
|
2008-10-09 |
2014-07-10 |
Tekmira Pharmaceuticals Corporation |
Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
|
AU2009305636A1
(en)
|
2008-10-15 |
2010-04-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of Factor 11 expression
|
NZ592867A
(en)
|
2008-10-20 |
2013-05-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin
|
WO2010048585A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
AU2009308217B2
(en)
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
KR101967417B1
(ko)
|
2008-11-10 |
2019-04-10 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
PE20120115A1
(es)
*
|
2008-11-17 |
2012-02-20 |
Hoffmann La Roche |
Composiciones y metodos para inhibir la expresion de genes del factor vii
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
CA2744207C
(en)
|
2008-11-24 |
2019-05-28 |
Northwestern University |
Polyvalent rna-nanoparticle compositions
|
EP2370451B1
(de)
|
2008-12-02 |
2016-11-16 |
Wave Life Sciences Japan, Inc. |
Verfahren zur synthese von am phosphoratom modifizierten nukleinsäuren
|
KR101749352B1
(ko)
|
2008-12-04 |
2017-06-20 |
큐알엔에이, 인크. |
Sirt1에 대한 천연 안티센스 전사체의 억제에 의해 sirt1 관련된 질환의 치료
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
CA2746003C
(en)
|
2008-12-04 |
2020-03-31 |
Opko Curna, Llc |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
CA2745811C
(en)
|
2008-12-04 |
2021-07-13 |
Joseph Collard |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
EP3225281A1
(de)
|
2008-12-10 |
2017-10-04 |
Alnylam Pharmaceuticals, Inc. |
Gegen gnaq gerichtete dsrna-zusammensetzungen und verfahren zur expressionshemmung
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
CA2750820A1
(en)
|
2009-01-27 |
2010-08-05 |
Qiagen Gaithersburg |
Thermophilic helicase dependent amplification technology with endpoint homogenous fluorescent detection
|
AU2010208035B2
(en)
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
AU2010211133A1
(en)
*
|
2009-02-03 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of PTP1B genes
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
EP3009150B1
(de)
|
2009-02-12 |
2019-11-13 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
|
KR101805199B1
(ko)
|
2009-02-12 |
2017-12-05 |
큐알엔에이, 인크. |
신경교세포 유래된 신경영양성 인자 (gdnf)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (gdnf) 관련된 질환의 치료
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
EP3424939A1
(de)
|
2009-03-02 |
2019-01-09 |
Alnylam Pharmaceuticals Inc. |
Chemische nukleinsäuremodifikationen
|
US20110319317A1
(en)
|
2009-03-04 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
EP2408920B1
(de)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
|
KR20120022938A
(ko)
|
2009-04-15 |
2012-03-12 |
노오쓰웨스턴 유니버시티 |
올리고뉴클레오티드 관능화된 나노입자의 전달
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
ES2661787T3
(es)
|
2009-05-01 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con hemoglobina (hbf/hbg) por inhibición de transcrito antisentido natural para hbf/hbg
|
NZ596186A
(en)
|
2009-05-05 |
2014-03-28 |
Alnylam Pharmaceuticals Inc |
Lipid compositions
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
KR101742334B1
(ko)
|
2009-05-08 |
2017-06-01 |
큐알엔에이, 인크. |
Dmd 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
|
WO2010132665A1
(en)
|
2009-05-15 |
2010-11-18 |
Yale University |
Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
|
KR20120069610A
(ko)
*
|
2009-05-15 |
2012-06-28 |
에프. 호프만-라 로슈 아게 |
글루코코르티코이드 수용체(gcr) 유전자의 발현을 억제하는 조성물 및 방법
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
EP2435571B1
(de)
|
2009-05-28 |
2016-12-14 |
CuRNA, Inc. |
Behandlung von durch antivirale gene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein antivirales gen
|
KR101766408B1
(ko)
|
2009-06-10 |
2017-08-10 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
EP2443238B1
(de)
|
2009-06-16 |
2017-03-22 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit paraoxonase 1 (pon1) mittels hemmung des natürlichen antisense-transkripts gegen pon 1
|
CN102597238B
(zh)
|
2009-06-24 |
2016-06-29 |
库尔纳公司 |
通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
|
WO2010151674A2
(en)
|
2009-06-26 |
2010-12-29 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
SG177564A1
(en)
|
2009-07-06 |
2012-02-28 |
Ontorii Inc |
Novel nucleic acid prodrugs and methods of use thereof
|
WO2011005861A1
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotide end caps
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
WO2011011700A2
(en)
|
2009-07-24 |
2011-01-27 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
JP6128848B2
(ja)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
CN102625841A
(zh)
|
2009-08-11 |
2012-08-01 |
欧科库尔纳有限责任公司 |
通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
WO2011022420A1
(en)
|
2009-08-17 |
2011-02-24 |
Yale University |
Methylation biomarkers and methods of use
|
CA2771228C
(en)
|
2009-08-21 |
2020-12-29 |
Opko Curna, Llc |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP6175236B2
(ja)
|
2009-09-25 |
2017-08-09 |
カッパーアールエヌエー,インコーポレイテッド |
フィラグリン(flg)の発現および活性の調整によるflg関連疾患の処置
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
WO2011056687A2
(en)
|
2009-10-27 |
2011-05-12 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
CA2779099C
(en)
|
2009-10-30 |
2021-08-10 |
Northwestern University |
Templated nanoconjugates
|
US20130084565A1
(en)
|
2009-11-03 |
2013-04-04 |
University Of Virginia Patent Foundation |
Versatile, visible method for detecting polymeric analytes
|
AR078921A1
(es)
|
2009-11-09 |
2011-12-14 |
Hoffmann La Roche |
Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
|
AU2010321576A1
(en)
|
2009-11-23 |
2012-06-07 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
CA2781887C
(en)
|
2009-11-30 |
2018-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
WO2011084455A2
(en)
|
2009-12-16 |
2011-07-14 |
Opko Curna, Llc. |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
KR101793753B1
(ko)
|
2009-12-23 |
2017-11-03 |
큐알엔에이, 인크. |
커플링방지 단백질 2(ucp2)에 대한 천연 안티센스 전사체의 저해에 의한 ucp2 관련 질환의 치료
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
EP2519633B1
(de)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem nuclear-respirator-faktor 1 (nrf1) mittels hemmung des natürlichen antisense-transkripts gegen nrf1
|
JP6083735B2
(ja)
|
2009-12-31 |
2017-02-22 |
カッパーアールエヌエー,インコーポレイテッド |
インスリン受容体基質2(irs2)および転写因子3(tfe3)に対する天然アンチセンス転写物の阻害によるインスリン受容体基質2(irs2)関連疾患の治療
|
NO2521784T3
(de)
|
2010-01-04 |
2018-05-05 |
|
|
US8912157B2
(en)
|
2010-01-06 |
2014-12-16 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
DK2524039T3
(en)
|
2010-01-11 |
2018-03-12 |
Curna Inc |
TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2524042A2
(de)
|
2010-01-12 |
2012-11-21 |
Yale University |
Strukturierte rna-motive sowie verbindungen und verfahren zu ihrer verwendung
|
WO2011091390A2
(en)
|
2010-01-25 |
2011-07-28 |
Opko Curna, Llc |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
US20130028889A1
(en)
|
2010-02-04 |
2013-01-31 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
US20110196016A1
(en)
*
|
2010-02-05 |
2011-08-11 |
Anke Geick |
Compositions and Methods for Inhibiting Expression of IKK2 Genes
|
WO2011103528A2
(en)
|
2010-02-22 |
2011-08-25 |
Opko Curna Llc |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
EP2538981B1
(de)
|
2010-02-23 |
2017-12-20 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und methoden zur diagnose und behandlung von tumoren
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
AU2011219029B2
(en)
|
2010-02-26 |
2017-02-02 |
Columbia University |
Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
WO2011112732A2
(en)
|
2010-03-12 |
2011-09-15 |
The Brigham And Women's Hospital, Inc. |
Methods of treating vascular inflammatory disorders
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
EP2550000A4
(de)
|
2010-03-24 |
2014-03-26 |
Advirna Inc |
Selbstfreisetzende rnai-verbindungen von reduzierter grösse
|
JP6060071B2
(ja)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
皮膚および線維症適用におけるrna干渉
|
US8889350B2
(en)
|
2010-03-26 |
2014-11-18 |
Swift Biosciences, Inc. |
Methods and compositions for isolating polynucleotides
|
ES2893199T3
(es)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
EP2553098B1
(de)
|
2010-04-02 |
2017-10-11 |
CuRNA, Inc. |
Behandlung von durch den koloniestimulierenden faktor 3 (csf3) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für csf3
|
US9044494B2
(en)
|
2010-04-09 |
2015-06-02 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
WO2011133871A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
5'-end derivatives
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
EP2625186B1
(de)
|
2010-04-28 |
2016-07-27 |
Ionis Pharmaceuticals, Inc. |
5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
EP2566966A4
(de)
|
2010-05-03 |
2013-12-11 |
Curna Inc |
Behandlung von sirtuin (sirt)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein sirtuin (sirt)
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
WO2011150007A2
(en)
|
2010-05-26 |
2011-12-01 |
Opko Curna Llc |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
WO2011150227A1
(en)
|
2010-05-26 |
2011-12-01 |
Qiagen Gaithersburg, Inc. |
Quantitative helicase assay
|
CA2799207C
(en)
|
2010-05-26 |
2019-03-26 |
Curna, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
TWI620756B
(zh)
|
2010-05-28 |
2018-04-11 |
薩羅塔治療公司 |
具有經修飾之單元間連結及/或末端基團之寡核苷酸類似物
|
WO2011153323A2
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CA2802049C
(en)
|
2010-06-07 |
2018-07-10 |
Firefly Bioworks, Inc. |
Scanning multifunctional particles
|
EP2580228B1
(de)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituierte 2 '-amino- und 2 '-thio-bicyclische nukleoside und daraus hergestellte oligomere verbindungen
|
US9638632B2
(en)
|
2010-06-11 |
2017-05-02 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
WO2011159836A2
(en)
|
2010-06-15 |
2011-12-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
WO2011163466A1
(en)
|
2010-06-23 |
2011-12-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (nrg-1)
|
CA2803882C
(en)
|
2010-06-23 |
2022-10-18 |
Opko Curna, Llc |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
WO2012012467A2
(en)
|
2010-07-19 |
2012-01-26 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130143955A1
(en)
|
2010-08-09 |
2013-06-06 |
Yale University |
Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
|
WO2012031243A2
(en)
|
2010-09-03 |
2012-03-08 |
Avi Biopharma, Inc. |
dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
EP2851426B1
(de)
|
2010-10-18 |
2018-08-22 |
Arrowhead Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression von RRM2-Genen
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
CN103201387B
(zh)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
EP3260540A1
(de)
|
2010-11-12 |
2017-12-27 |
The General Hospital Corporation |
Polycombassoziierte nichtcodierende rnas
|
EP2640853B1
(de)
|
2010-11-17 |
2018-12-26 |
Ionis Pharmaceuticals, Inc. |
Modulation von alpha-synukleinexpression
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
WO2012071238A2
(en)
|
2010-11-23 |
2012-05-31 |
Opko Curna Llc |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
DK3202760T3
(da)
|
2011-01-11 |
2019-11-25 |
Alnylam Pharmaceuticals Inc |
Pegylerede lipider og deres anvendelse til lægemiddelfremføring
|
WO2012097261A2
(en)
|
2011-01-14 |
2012-07-19 |
The General Hospital Corporation |
Methods targeting mir-128 for regulating cholesterol/lipid metabolism
|
SI2670411T1
(sl)
|
2011-02-02 |
2019-06-28 |
Excaliard Pharmaceuticals, Inc. |
Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
|
EP2670404B1
(de)
|
2011-02-02 |
2018-08-29 |
The Trustees of Princeton University |
Sirtuin-modulatoren als modulatoren der virusproduktion
|
WO2012109157A2
(en)
|
2011-02-07 |
2012-08-16 |
The Governing Council Of The University Of Toronto |
Bioprobes and methods of use thereof
|
EP3467109A1
(de)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
WO2012138453A1
(en)
|
2011-04-03 |
2012-10-11 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified rna (mod-rna)
|
US20140186844A1
(en)
|
2011-04-26 |
2014-07-03 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
KR102395085B1
(ko)
|
2011-06-21 |
2022-05-09 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
|
CN112111492A
(zh)
|
2011-06-21 |
2020-12-22 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9222093B2
(en)
|
2011-06-30 |
2015-12-29 |
The University Of Hong Kong |
Two-way, portable riboswitch mediated gene expression control device
|
DK2726613T3
(en)
|
2011-06-30 |
2018-12-03 |
Arrowhead Pharmaceuticals Inc |
COMPOSITIONS AND PROCEDURES FOR INHIBITING GENEPRESSION OF HEPATITIS B VIRUS
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
RU2014105311A
(ru)
|
2011-07-19 |
2015-08-27 |
Уэйв Лайф Сайенсес Пте. Лтд. |
Способы синтеза функционализованных нуклеиновых кислот
|
EP2739735A2
(de)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
|
EP2742136B1
(de)
|
2011-08-11 |
2017-09-27 |
Ionis Pharmaceuticals, Inc. |
Gapmerverbindungen mit 5'-modifizierten desoxyribonukleotiden im gap und verwendungen davon
|
EP2751269B1
(de)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Verfahren und verbindungen für erkrankungen im zusammenhang mit repeat-expansion
|
DK2751270T3
(en)
|
2011-08-29 |
2018-10-29 |
Ionis Pharmaceuticals Inc |
OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
|
US10583128B2
(en)
|
2011-09-06 |
2020-03-10 |
Curna, Inc. |
Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
|
EP2755692B1
(de)
|
2011-09-14 |
2020-11-25 |
Northwestern University |
Nanokonjugate zur durchquerung der blut-hirn-schranke
|
EP2756080B1
(de)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimere oligonukleotidverbindungen
|
US9580713B2
(en)
|
2011-09-17 |
2017-02-28 |
Yale University |
Fluoride-responsive riboswitches, fluoride transporters, and methods of use
|
CA2849476A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
EP2766482B1
(de)
|
2011-10-11 |
2016-12-07 |
The Brigham and Women's Hospital, Inc. |
Mikro-rnas in neurodegenerativen erkrankungen
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
EA035030B1
(ru)
|
2011-11-18 |
2020-04-20 |
Сарепта Терапьютикс, Инк. |
Модифицированные морфолиновые аналоги олигонуклеотидов
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
EP2790736B1
(de)
|
2011-12-12 |
2018-01-31 |
Oncoimmunin, Inc. |
In-vivo-verabreichung von oligonucleotiden
|
WO2013106770A1
(en)
|
2012-01-11 |
2013-07-18 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of ikbkap splicing
|
US8846885B2
(en)
|
2012-02-17 |
2014-09-30 |
Ajinomoto Co., Inc. |
Oligonucleotide with protected base
|
IN2014DN06768A
(de)
*
|
2012-02-17 |
2015-05-22 |
Ajinomoto Kk |
|
SG11201405669XA
(en)
|
2012-03-13 |
2014-10-30 |
Swift Biosciences Inc |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
JP2015511494A
(ja)
|
2012-03-15 |
2015-04-20 |
キュアナ,インク. |
脳由来神経栄養因子(bdnf)に対する天然アンチセンス転写物の阻害によるbdnf関連の疾患の処置
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
WO2013142255A2
(en)
|
2012-03-22 |
2013-09-26 |
University Of Miami |
Multi-specific binding agents
|
AU2013202595B2
(en)
|
2012-03-30 |
2016-04-21 |
Biogen Ma Inc. |
Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
EP2839006B1
(de)
|
2012-04-20 |
2018-01-03 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
JP2015518485A
(ja)
|
2012-04-20 |
2015-07-02 |
アプタミアール セラピューティクス インコーポレイテッド |
熱発生のmiRNA調節剤
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2841572B1
(de)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetische korrektur mutierter gene
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
AU2013262663A1
(en)
|
2012-05-16 |
2015-01-22 |
The General Hospital Corporation D/B/A Massachusetts General Hospital |
Compositions and methods for modulating gene expression
|
EA201492123A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов smn
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
US9828602B2
(en)
|
2012-06-01 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
WO2013185097A1
(en)
|
2012-06-08 |
2013-12-12 |
The Regents Of The University Of Michigan |
Ultrasound-triggerable agents for tissue engineering
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
US9982257B2
(en)
|
2012-07-13 |
2018-05-29 |
Wave Life Sciences Ltd. |
Chiral control
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
WO2014022852A1
(en)
|
2012-08-03 |
2014-02-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
CN104736551B
(zh)
|
2012-08-15 |
2017-07-28 |
Ionis制药公司 |
使用改进的封端方案制备寡聚化合物的方法
|
CA2884245C
(en)
|
2012-09-06 |
2023-03-14 |
The University Of Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
EP4144845A1
(de)
|
2012-10-12 |
2023-03-08 |
Ionis Pharmaceuticals, Inc. |
Antisense-verbindungen und verwendungen davon
|
DK2906256T3
(en)
|
2012-10-12 |
2018-11-19 |
Ionis Pharmaceuticals Inc |
SELECTIVE ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US10548962B2
(en)
|
2012-10-22 |
2020-02-04 |
The Board Of Regents For Oklahoma State University |
Use of the salmonella SPP type III secretion proteins as a protective vaccination
|
US9950053B2
(en)
|
2012-10-22 |
2018-04-24 |
The Board Of Regents For Oklahoma State University |
Use of the Salmonella SPP type III secretion proteins as a protective vaccination
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
US9695475B2
(en)
|
2012-12-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Competitive modulation of microRNAs
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014121287A2
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
KR20150130430A
(ko)
|
2013-03-14 |
2015-11-23 |
아이시스 파마수티컬즈 인코포레이티드 |
타우 발현을 조절하는 조성물 및 방법
|
BR112015022621A2
(pt)
|
2013-03-14 |
2017-10-31 |
Andes Biotechnologies S A |
métodos para detecção e tratamento de mieloma múltiplo
|
ES2708650T3
(es)
|
2013-03-14 |
2019-04-10 |
Andes Biotechnologies Global Inc |
Oligonucleótidos antisentido para el tratamiento de células madre tumorales
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
US9347095B2
(en)
|
2013-03-15 |
2016-05-24 |
Bio-Rad Laboratories, Inc. |
Digital assays for mutation detection
|
EP2978446B1
(de)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antikörper zur behandlung von morbus alzheimer
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
WO2015012916A2
(en)
|
2013-04-23 |
2015-01-29 |
Northwestern University |
Metal-ligand coordination polymer nanoparticles and methods for making
|
SG10201906382QA
(en)
|
2013-05-01 |
2019-08-27 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating hbv and ttr expression
|
TWI727917B
(zh)
|
2013-05-22 |
2021-05-21 |
美商阿尼拉製藥公司 |
TMPRSS6iRNA 組成物及其使用方法
|
RS57418B1
(sr)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals Inc |
Serpina1 irnk sastavi i postupci njihove primene
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
AU2014280847B2
(en)
|
2013-06-13 |
2019-07-04 |
Antisense Therapeutics Ltd |
Combination therapy
|
CA2916252A1
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
EP3022176B8
(de)
|
2013-07-15 |
2019-12-25 |
The Regents of the University of California |
Eingeschränkte azacyclische analoga von fty720
|
TWI657819B
(zh)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
ES2773547T3
(es)
|
2013-08-08 |
2020-07-13 |
Scripps Research Inst |
Un procedimiento de marcaje enzimático específico de sitio de ácidos nucleicos in vitro mediante la incorporación de nucleótidos no naturales
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
CN105793423A
(zh)
|
2013-10-02 |
2016-07-20 |
阿尔尼拉姆医药品有限公司 |
用于抑制lect2基因表达的组合物和方法
|
EP3052107B1
(de)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organische verbindungen zur behandlung von hepatitis-b-infektionen
|
JP6613227B2
(ja)
|
2013-10-04 |
2019-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Alas1遺伝子の発現を阻害する組成物および方法
|
EP3052464B1
(de)
|
2013-10-04 |
2020-04-15 |
Novartis AG |
3 endkappen für rnai-mittel zur verwendung in der rna-interferenz
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
CN105899679A
(zh)
|
2013-10-21 |
2016-08-24 |
通用医疗公司 |
与循环肿瘤细胞簇有关的方法以及癌症的治疗
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
US10752940B2
(en)
|
2013-11-08 |
2020-08-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
ES2797679T3
(es)
|
2013-12-02 |
2020-12-03 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido y usos de los mismos
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
WO2015126502A2
(en)
|
2013-12-03 |
2015-08-27 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
WO2015085113A1
(en)
|
2013-12-04 |
2015-06-11 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complementary component irna compositions and methods for using them
|
CN111729090A
(zh)
|
2013-12-20 |
2020-10-02 |
通用医疗公司 |
与循环肿瘤细胞相关的方法和测定法
|
US9274117B2
(en)
|
2013-12-21 |
2016-03-01 |
Catholic University Industry Academic |
Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
US10149905B2
(en)
|
2014-01-15 |
2018-12-11 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
DK3094728T3
(da)
|
2014-01-16 |
2022-05-16 |
Wave Life Sciences Ltd |
Kiralt design
|
CA3228845A1
(en)
|
2014-01-31 |
2015-08-06 |
Temple University Of The Commonwealth System Of Higher Education |
Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
|
EP3102197B1
(de)
|
2014-02-04 |
2018-08-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
WO2015123264A1
(en)
|
2014-02-11 |
2015-08-20 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP3119789B1
(de)
|
2014-03-17 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Bicyclische carbocyclische nukleoside und daraus hergestellte oligomere verbindungen
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
RU2019130898A
(ru)
|
2014-03-19 |
2019-11-11 |
Ионис Фармасьютикалз, Инк. |
Композиции для модуляции экспрессии атаксина 2
|
RU2704619C2
(ru)
|
2014-04-01 |
2019-10-30 |
Биоген Ма Инк. |
Композиции для модулирования экспрессии sod-1
|
EP3943607A1
(de)
|
2014-04-09 |
2022-01-26 |
The Scripps Research Institute |
Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
|
US10221416B2
(en)
|
2014-04-24 |
2019-03-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
DK3137476T3
(da)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
Linker-modificerede oligomerforbindelser
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
SI3137605T1
(sl)
|
2014-05-01 |
2021-02-26 |
Ionis Pharmaceuticals, Inc. |
Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
|
EP3137604B1
(de)
|
2014-05-01 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulierung der wachstumshormonrezeptorexpression
|
CA2947619A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
EA201692370A1
(ru)
|
2014-05-22 |
2017-03-31 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
BR112016028211A2
(pt)
|
2014-06-02 |
2017-10-24 |
Childrens Medical Center |
métodos e composições para imunomodulação
|
CN106661580B
(zh)
|
2014-06-10 |
2022-02-15 |
鹿特丹伊拉斯谟大学医疗中心 |
用于治疗庞帕病的反义寡核苷酸
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
EP3161159B1
(de)
|
2014-06-25 |
2020-08-05 |
The General Hospital Corporation |
Targeting von humanem satellit ii (hsatii)
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
MX2017001432A
(es)
|
2014-07-31 |
2017-05-09 |
Uab Res Found |
Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
|
CA2958431A1
(en)
|
2014-08-19 |
2016-02-25 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
CN107074767A
(zh)
|
2014-08-20 |
2017-08-18 |
西北大学 |
用于反义基因调节的生物相容的无限配位聚合物纳米颗粒–核酸缀合物
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
CN107106704A
(zh)
|
2014-08-29 |
2017-08-29 |
儿童医疗中心有限公司 |
用于治疗癌症的方法和组合物
|
WO2016033326A2
(en)
|
2014-08-29 |
2016-03-03 |
Alnylam Pharmaceuticals, Inc. |
Methods of treating transthyretin (ttr) mediated amyloidosis
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
WO2016044271A2
(en)
|
2014-09-15 |
2016-03-24 |
Children's Medical Center Corporation |
Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
|
EP3198012B1
(de)
|
2014-09-26 |
2019-09-04 |
University of Massachusetts |
Rna-modulierende stoffe
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016057693A1
(en)
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
EP3207138B1
(de)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
|
EP3212773B1
(de)
|
2014-10-29 |
2021-09-15 |
Massachusetts Eye and Ear Infirmary |
Effiziente abgabe von therapeutischen molekülen an zellen des innenohres
|
WO2016069912A1
(en)
|
2014-10-29 |
2016-05-06 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
EP3212794B1
(de)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016077540A1
(en)
|
2014-11-12 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of comp
|
CN107250362B
(zh)
|
2014-11-17 |
2021-10-22 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
CN107106493A
(zh)
|
2014-11-21 |
2017-08-29 |
西北大学 |
球形核酸纳米颗粒缀合物的序列特异性细胞摄取
|
EP3229842B1
(de)
|
2014-12-08 |
2022-07-06 |
The Board of Regents of The University of Texas System |
Lipokationische polymere und verwendungen davon
|
JP6997623B2
(ja)
|
2014-12-12 |
2022-02-04 |
エム. ウルフ、トッド |
オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
JP2018506715A
(ja)
|
2015-01-23 |
2018-03-08 |
ヴァンダービルト ユニバーシティー |
堅固なインターフェロメーター及びその使用方法
|
EP3256487A4
(de)
|
2015-02-09 |
2018-07-18 |
Duke University |
Zusammensetzungen und verfahren zur epigenombearbeitung
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP3262173A2
(de)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
MX2017012407A
(es)
|
2015-03-27 |
2018-03-07 |
Harvard College |
Celulas t modificadas y métodos para hacer y usar las mismas.
|
WO2016164463A1
(en)
|
2015-04-07 |
2016-10-13 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive x chromosome
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
PL3283500T3
(pl)
|
2015-04-08 |
2021-05-31 |
The University Of Chicago |
Kompozycje i sposoby korygowania dystrofii mięśniowej obręczowo-kończynowej typu 2c z użyciem pominięcia egzonu
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
WO2016196897A1
(en)
|
2015-06-04 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
CN108139375A
(zh)
|
2015-06-26 |
2018-06-08 |
贝斯以色列女执事医疗中心股份有限公司 |
靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
|
EP3313989A4
(de)
|
2015-06-29 |
2018-12-05 |
Ionis Pharmaceuticals, Inc. |
Modifizierte crispr-rna und modifizierte single-crispr-rna und verwendungen davon
|
EP3314027A4
(de)
|
2015-06-29 |
2019-07-03 |
Caris Science, Inc. |
Therapeutische oligonukleotide
|
CA2991598A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
MY192997A
(en)
|
2015-07-10 |
2022-09-20 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
EP3919619A1
(de)
|
2015-07-17 |
2021-12-08 |
Alnylam Pharmaceuticals, Inc. |
Mehrfach gerichtete einheitlichen konjugate
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
CA2993652A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
WO2017021961A1
(en)
|
2015-08-04 |
2017-02-09 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 rnai 치료법
|
CN114525280A
(zh)
|
2015-09-02 |
2022-05-24 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
CN108271360B
(zh)
|
2015-09-14 |
2023-01-24 |
得克萨斯州大学系统董事会 |
亲脂阳离子树枝状聚合物及其用途
|
CA2999177A1
(en)
|
2015-09-24 |
2017-03-30 |
The Regents Of The University Of California |
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
|
RU2018113709A
(ru)
|
2015-09-24 |
2019-10-30 |
Айонис Фармасьютикалз, Инк. |
Модуляторы экспрессии kras
|
AU2016339053A1
(en)
|
2015-09-24 |
2018-04-12 |
Crispr Therapeutics Ag |
Novel family of RNA-programmable endonucleases and their uses in genome editing and other applications
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
WO2017058672A1
(en)
|
2015-09-29 |
2017-04-06 |
The Regents Of The University Of Michigan Office Of Technology Transfer |
Biodegradable hydrogel for tissue expansion
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
JP2018531037A
(ja)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物
|
EP3368063B1
(de)
|
2015-10-28 |
2023-09-06 |
Vertex Pharmaceuticals Inc. |
Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
|
SI3368578T1
(sl)
|
2015-10-30 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti HtrA1 in postopki uporabe
|
WO2017075670A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
US20190046555A1
(en)
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
BR112018008971A2
(pt)
|
2015-11-06 |
2018-11-27 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
|
PE20181180A1
(es)
|
2015-11-06 |
2018-07-20 |
Ionis Pharmaceuticals Inc |
MODULAR LA EXPRESION DE APOLIPOPROTEINA (a)
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
EP3967758A1
(de)
|
2015-12-01 |
2022-03-16 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von alpha-1-antitrypsin-defizienz
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
AU2015416656B2
(en)
|
2015-12-07 |
2023-02-23 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for Pompe disease
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
AU2016376191A1
(en)
|
2015-12-23 |
2018-07-12 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
WO2017132483A1
(en)
|
2016-01-29 |
2017-08-03 |
Vanderbilt University |
Free-solution response function interferometry
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
US20190112353A1
(en)
|
2016-02-18 |
2019-04-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
JP7033072B2
(ja)
|
2016-02-25 |
2022-03-09 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
Smoc2を標的化する線維症のための治療方法
|
CA3016592A1
(en)
|
2016-03-04 |
2017-09-08 |
Rhode Island Hospital |
Targeting microrna for cancer treatment
|
US11136577B2
(en)
|
2016-03-09 |
2021-10-05 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting PMP22 expression
|
WO2017158422A1
(en)
|
2016-03-16 |
2017-09-21 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
JP2019516393A
(ja)
|
2016-03-18 |
2019-06-20 |
カリス サイエンス インコーポレイテッド |
オリゴヌクレオチドプローブおよびその使用
|
ES2933435T3
(es)
|
2016-04-13 |
2023-02-08 |
Ionis Pharmaceuticals Inc |
Métodos para reducir la expresión de C9ORF72
|
AU2017252023A1
(en)
|
2016-04-18 |
2018-11-15 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
CN109414408B
(zh)
|
2016-05-16 |
2022-03-29 |
得克萨斯州大学系统董事会 |
阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
|
WO2017205686A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
US11708614B2
(en)
|
2016-06-15 |
2023-07-25 |
Streck Llc |
Assays and methods for determining microbial resistance
|
EP3471781A4
(de)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Modulierung der gys1-expression
|
WO2017223528A1
(en)
|
2016-06-24 |
2017-12-28 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
WO2018002812A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
WO2018002783A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
AU2017292173B2
(en)
|
2016-07-06 |
2022-01-13 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
EP3481856A1
(de)
|
2016-07-06 |
2019-05-15 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schmerzbedingten erkrankungen
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
US11253601B2
(en)
|
2016-07-11 |
2022-02-22 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
RS63928B1
(sr)
|
2016-07-15 |
2023-02-28 |
Ionis Pharmaceuticals Inc |
Jedinjenja i metode za modulaciju smn2
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
SG10201607303YA
(en)
|
2016-09-01 |
2018-04-27 |
Agency Science Tech & Res |
Antisense oligonucleotides to induce exon skipping
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
SG10201609048RA
(en)
|
2016-10-28 |
2018-05-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
EP3555296A4
(de)
|
2016-12-13 |
2020-07-29 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Verfahren zur exogenen wirkstoffaktivierung von chemisch induzierten signalisierungskomplexen, die in vitro und in vivo in manipulierten zellen exprimiert werden
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
BR112019014282A2
(pt)
|
2017-01-10 |
2020-03-03 |
Arrowhead Pharmaceuticals, Inc. |
Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
|
US11197928B2
(en)
|
2017-01-13 |
2021-12-14 |
Board Of Regents, The University Of Texas System |
Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
|
IL301053A
(en)
|
2017-01-23 |
2023-05-01 |
Regeneron Pharma |
HSD17B13 variants and their uses
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
EP3585900B1
(de)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materialien und methoden zur behandlung von spinocerebellar ataxia typ 2 (sca2) und anderen spinocerebellar ataxia typ 2 protein (atxn2) gen verwandten erkrankungen oder störungen
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
EP3585807A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung der parkinson-krankheit im frühstadium (park1) und anderer zustände oder störungen im zusammenhang mit dem synuclein-alpha (snca)-gen
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
US20180284123A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
|
US11203611B2
(en)
|
2017-04-14 |
2021-12-21 |
Tollnine, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
AU2018254437A1
(en)
|
2017-04-18 |
2019-11-28 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis B virus (HBV) infection
|
JP2020517613A
(ja)
|
2017-04-20 |
2020-06-18 |
シンセナ アーゲー |
トリシクロdnaヌクレオシドを含む改変オリゴマー化合物およびその使用
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
EP3612232A1
(de)
|
2017-04-21 |
2020-02-26 |
The Broad Institute, Inc. |
Gezielte abgabe an beta-zellen
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
US11622977B2
(en)
|
2017-05-12 |
2023-04-11 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
EP3645546A4
(de)
|
2017-06-30 |
2021-12-01 |
Solstice Biologics, Ltd. |
Chirale phosphoramidithilfsmittel und verfahren zu ihrer verwendung
|
CN111051512A
(zh)
|
2017-07-11 |
2020-04-21 |
辛索克斯公司 |
非天然核苷酸的掺入及其方法
|
EP3652186A4
(de)
|
2017-07-13 |
2021-03-31 |
Northwestern University |
Allgemeines und direktes verfahren zur herstellung von oligonukleotidfunktionalisierten metallorganischen gerüstnanopartikeln
|
WO2019014530A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
LACTATE DEHYDROGENASE A (LDHA) RNAI COMPOSITIONS AND METHODS OF USE
|
WO2019028425A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CONJUGATES OF CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
US11806360B2
(en)
|
2017-09-19 |
2023-11-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
SG11202003464VA
(en)
|
2017-10-17 |
2020-05-28 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
US20210180091A1
(en)
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
US20210032622A1
(en)
|
2017-11-09 |
2021-02-04 |
Crispr Therapeutics Ag |
Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
EP3714054A1
(de)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
|
CN111727251A
(zh)
|
2017-11-21 |
2020-09-29 |
克里斯珀医疗股份公司 |
用于治疗常染色体显性色素性视网膜炎的材料和方法
|
US20200384033A1
(en)
|
2017-12-05 |
2020-12-10 |
Vertex Pharmaceuticals Incorporated |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
WO2019118916A1
(en)
|
2017-12-14 |
2019-06-20 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
AU2018388484A1
(en)
|
2017-12-18 |
2020-07-30 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (HMGB1) iRNA compositions and methods of use thereof
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
EP3728595A1
(de)
|
2017-12-21 |
2020-10-28 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
JP7348185B2
(ja)
|
2017-12-21 |
2023-09-20 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
キラル富化二本鎖rna剤
|
WO2019140231A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
WO2019142135A1
(en)
|
2018-01-19 |
2019-07-25 |
Synthena Ag |
Tricyclo-dna nucleoside precursors and processes for preparing the same
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
MA51788A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes pour traiter des hémoglobinopathies
|
MA51787A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes de traitement d'hémoglobinopathies
|
JP7317029B2
(ja)
|
2018-02-12 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
修飾化合物及びその使用
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
KR20200127207A
(ko)
|
2018-02-26 |
2020-11-10 |
신톡스, 인크. |
Il-15 접합체 및 이의 용도
|
TW202000199A
(zh)
|
2018-03-02 |
2020-01-01 |
美商Ionis製藥公司 |
Irf4 表現之調節劑
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
EP3768834A1
(de)
|
2018-03-19 |
2021-01-27 |
CRISPR Therapeutics AG |
Neuartige rna-programmierbare endonukleasesysteme und verwendungen davon
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
EP4051799A2
(de)
|
2018-03-30 |
2022-09-07 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Aptamere zur gezielten aktivierung von t-zellvermittelter immunität
|
CN116536272A
(zh)
|
2018-04-06 |
2023-08-04 |
儿童医疗中心有限公司 |
用于体细胞重新编程和调整印记的组合物和方法
|
SG11202008660TA
(en)
|
2018-04-11 |
2020-10-29 |
Ionis Pharmaceuticals Inc |
Modulators of ezh2 expression
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
US10907161B2
(en)
|
2018-04-19 |
2021-02-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
WO2019213571A1
(en)
|
2018-05-03 |
2019-11-07 |
The Trustees Of Wheaton College |
Improved membranes for nanopore sensing applications
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
CR20200604A
(es)
|
2018-05-09 |
2021-02-09 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir de la expresión de atxn3
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
US11332746B1
(en)
|
2018-06-27 |
2022-05-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing LRRK2 expression
|
MX2021000922A
(es)
|
2018-07-25 |
2021-03-31 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de la atxn2.
|
BR112021001613A2
(pt)
|
2018-08-13 |
2021-05-04 |
Alnylam Pharmaceuticals, Inc. |
agentes de ácido ribonucleico de fita dupla, célula, composições farmacêuticas, métodos de inibição da expressão gênica, de inibição da replicação e de tratar um sujeito, métodos para reduzir o nível de um antígeno e para reduzir a carga viral e uso de um agente de dsrna
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
AU2019325255A1
(en)
|
2018-08-20 |
2021-04-15 |
Rogcon, Inc. |
Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
EP3620520A1
(de)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Neuartiges target zur behandlung einer stoffwechselerkrankung in einem individuum
|
US20220056220A1
(en)
|
2018-09-14 |
2022-02-24 |
Northwestern University |
Programming protein polymerization with dna
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
US20210348159A1
(en)
|
2018-10-17 |
2021-11-11 |
Crispr Therapeutics Ag |
Compositions and methods for delivering transgenes
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
BR112021008967A2
(pt)
|
2018-11-15 |
2021-08-17 |
Ionis Pharmaceuticals, Inc. |
moduladores da expressão de irf5
|
TW202039841A
(zh)
|
2018-11-21 |
2020-11-01 |
美商Ionis製藥公司 |
用於減少朊病毒表現之化合物及方法
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
EP4285929A3
(de)
|
2018-12-20 |
2024-03-06 |
Humabs Biomed SA |
Kombinierte hbv-therapie
|
WO2020132521A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
KR20210117271A
(ko)
|
2018-12-21 |
2021-09-28 |
노쓰웨스턴유니버시티 |
근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
|
WO2020139977A1
(en)
|
2018-12-26 |
2020-07-02 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
US11452738B2
(en)
|
2019-01-04 |
2022-09-27 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
|
SG11202107669WA
(en)
|
2019-01-16 |
2021-08-30 |
Genzyme Corp |
Serpinc1 irna compositions and methods of use thereof
|
JP2022519532A
(ja)
|
2019-01-31 |
2022-03-24 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Yap1発現のモジュレーター
|
AU2020218203A1
(en)
|
2019-02-06 |
2021-08-26 |
Synthorx, Inc. |
IL-2 conjugates and methods of use thereof
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
AU2020227824A1
(en)
|
2019-02-27 |
2021-08-26 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
US20220175956A1
(en)
|
2019-03-06 |
2022-06-09 |
Northwestern University |
Hairpin-like oligonucleotide-conjugated spherical nucleic acid
|
CA3139919A1
(en)
|
2019-03-11 |
2020-09-17 |
Ochsner Health System |
Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
|
SG11202109741VA
(en)
|
2019-03-12 |
2021-10-28 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
WO2020205463A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
BR112021022806A2
(pt)
|
2019-05-13 |
2022-01-25 |
Vir Biotechnology Inc |
Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit
|
WO2020243644A1
(en)
|
2019-05-31 |
2020-12-03 |
Streck, Inc. |
Detection of antibiotic resistance genes
|
US11879145B2
(en)
|
2019-06-14 |
2024-01-23 |
The Scripps Research Institute |
Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
|
CN114340664A
(zh)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
|
US20220305107A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
EP3956450A4
(de)
|
2019-07-26 |
2022-11-16 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation von gfap
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
CN114555128A
(zh)
|
2019-08-15 |
2022-05-27 |
新索思股份有限公司 |
采用il-2缀合物的免疫肿瘤学组合疗法
|
EP4013767A4
(de)
|
2019-08-15 |
2023-10-25 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomere verbindungen und ihre verwendungen
|
KR20220051355A
(ko)
|
2019-08-23 |
2022-04-26 |
신톡스, 인크. |
Il-15 콘쥬게이트 및 이의 용도
|
EP4025694A1
(de)
|
2019-09-03 |
2022-07-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum hemmen der lect2-genexpression
|
WO2021050554A1
(en)
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
JP2022552249A
(ja)
|
2019-10-14 |
2022-12-15 |
アストラゼネカ・アクチエボラーグ |
Pnpla3発現のモジュレーター
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
AU2020372478A1
(en)
|
2019-10-23 |
2022-06-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
WO2021086623A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Wheaton College |
Design and characterization of multilayered structures for support of lipid bilayers
|
TW202132567A
(zh)
|
2019-11-01 |
2021-09-01 |
美商阿尼拉製藥公司 |
亨汀頓蛋白(HTT)iRNA劑組成物及其使用方法
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
JP2022554272A
(ja)
|
2019-11-04 |
2022-12-28 |
シンソークス, インコーポレイテッド |
インターロイキン10コンジュゲートおよびその使用
|
CN115135765A
(zh)
|
2019-11-08 |
2022-09-30 |
菲奥医药公司 |
用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸
|
WO2021096763A1
(en)
|
2019-11-13 |
2021-05-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
JP2023503635A
(ja)
|
2019-11-27 |
2023-01-31 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフト |
Rna分子を合成する方法
|
MX2022006433A
(es)
|
2019-12-13 |
2022-06-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72) y metodos de uso de los mismos.
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP4077674A1
(de)
|
2019-12-18 |
2022-10-26 |
Alia Therapeutics S.R.L. |
Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
|
WO2021138537A1
(en)
|
2019-12-31 |
2021-07-08 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
CN115427571A
(zh)
|
2020-02-10 |
2022-12-02 |
阿尔尼拉姆医药品有限公司 |
沉默vegf-a表达的组合物和方法
|
MX2022010052A
(es)
|
2020-02-18 |
2022-09-05 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) contra la apolipoproteina c3 (apoc3) y metodos para su uso.
|
CA3169523A1
(en)
|
2020-02-28 |
2021-09-02 |
Jaume Pons |
Transglutaminase-mediated conjugation
|
TW202140787A
(zh)
|
2020-02-28 |
2021-11-01 |
美商Ionis製藥公司 |
用於調節smn2之化合物及方法
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
CA3174725A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
US20230295622A1
(en)
|
2020-04-06 |
2023-09-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
CN116134135A
(zh)
|
2020-04-07 |
2023-05-16 |
阿尔尼拉姆医药品有限公司 |
用于沉默scn9a表达的组合物和方法
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
BR112022021813A2
(pt)
|
2020-04-27 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de agente de apolipoproteína e (apoe) irna e métodos de uso das mesmas
|
IL297680A
(en)
|
2020-04-30 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
IRNA compounds complement factor b (cfb) and methods of using them
|
EP4143321A2
(de)
|
2020-05-01 |
2023-03-08 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulierung von atxn1
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
EP4150088A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4150087A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
|
EP4150090A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
BR112022024420A2
(pt)
|
2020-06-18 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
|
CA3182458A1
(en)
|
2020-06-24 |
2021-12-30 |
Laura ROSEN |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
AU2021296622A1
(en)
|
2020-06-25 |
2023-02-23 |
Synthorx, Inc. |
Immuno oncology combination therapy with IL-2 conjugates and anti-EGFR antibodies
|
JP2023532518A
(ja)
|
2020-06-29 |
2023-07-28 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Plp1を調節するための化合物及び方法
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
US20230392134A1
(en)
|
2020-09-30 |
2023-12-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
MX2023004029A
(es)
|
2020-10-09 |
2023-04-27 |
Synthorx Inc |
Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
|
BR112023006024A2
(pt)
|
2020-10-09 |
2023-05-09 |
Synthorx Inc |
Terapias de imuno-oncologia com conjugados de il-2
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2023549500A
(ja)
|
2020-11-13 |
2023-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
凝固第V因子(F5)iRNA組成物およびその使用方法
|
US11447521B2
(en)
|
2020-11-18 |
2022-09-20 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
CA3202708A1
(en)
|
2020-11-23 |
2022-05-27 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
BR112023012377A2
(pt)
|
2020-12-23 |
2023-10-24 |
Flagship Pioneering Innovations Vi Llc |
Composições de trems modificadas e usos das mesmas
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202245843A
(zh)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
|
TW202305131A
(zh)
|
2021-02-12 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
用於治療或預防超氧歧化酶1-(SOD1-)相關的神經退化疾病的超氧歧化酶1(SOD1)iRNA組成物及其使用方法
|
WO2022174102A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
WO2022182574A1
(en)
|
2021-02-26 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2022231003A1
(en)
|
2021-03-04 |
2023-09-14 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
US20220288181A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
JP2024512635A
(ja)
|
2021-03-29 |
2024-03-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ハンチンチン(HTT)iRNA剤組成物およびその使用方法
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
TW202309291A
(zh)
|
2021-04-07 |
2023-03-01 |
法商新植物Sas公司 |
用於室內空氣修復之組合物及方法
|
AU2022261124A1
(en)
|
2021-04-22 |
2023-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
KR20240001207A
(ko)
|
2021-04-26 |
2024-01-03 |
알닐람 파마슈티칼스 인코포레이티드 |
막관통 프로테아제, 세린 6(TMPRSS6) iRNA 조성물 및 이의 사용 방법
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4334448A1
(de)
|
2021-05-03 |
2024-03-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von transthyretin(ttr)-vermittelter amyloidose
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
TW202313679A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
|
WO2022256290A2
(en)
|
2021-06-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
KR20240021218A
(ko)
|
2021-06-11 |
2024-02-16 |
바이엘 악티엔게젤샤프트 |
신규 유형 v rna 프로그래밍가능 엔도뉴클레아제 시스템
|
CN117500815A
(zh)
|
2021-06-18 |
2024-02-02 |
Ionis制药公司 |
用于降低ifnar1表达的化合物和方法
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CA3225469A1
(en)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
IL309905A
(en)
|
2021-07-23 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions in β-catenin (CTNNB1) and methods of using them
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
IL310244A
(en)
|
2021-08-03 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Transthyretin (TTR) IRNA compositions and methods of using them
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
WO2023015265A2
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
AU2022328347A1
(en)
|
2021-08-13 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
WO2023034870A2
(en)
|
2021-09-01 |
2023-03-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dmpk expression
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
EP4311579A1
(de)
|
2022-07-29 |
2024-01-31 |
Association Française contre les Myopathies |
B-zell-spezifische mabsirna-konjugate verbessern myasthenie
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024044352A1
(en)
|
2022-08-26 |
2024-02-29 |
The General Hospital Corporation |
Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|